PTEN haploinsufficiency leads to prostate lesions in mouse transgenic models but not to malignant tumors, so this alteration is often combined with additional genetic changes such as Rb or p53 inactivation in tumor models to mimic more closely the clinical situation [124]. Here, TP53 is linked to neoplasm.